A new trading day began on Monday, with Mirum Pharmaceuticals Inc (NASDAQ: MIRM) stock price up 6.49% from the previous day of trading, before settling in for the closing price of $41.32. MIRM’s price has ranged from $23.14 to $48.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 111.13%. Meanwhile, its annual earnings per share averaged 58.79%. With a float of $38.32 million, this company’s outstanding shares have now reached $47.97 million.
Let’s determine the extent of company efficiency that accounts for 264 employees. In terms of profitability, gross margin is 73.47%, operating margin of -30.44%, and the pretax margin is -31.09%.
Mirum Pharmaceuticals Inc (MIRM) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Mirum Pharmaceuticals Inc is 20.21%, while institutional ownership is 94.22%. The most recent insider transaction that took place on Jan 07 ’25, was worth 85,545. In this transaction PRESIDENT AND COO of this company sold 1,998 shares at a rate of $42.82, taking the stock ownership to the 27,015 shares. Before that another transaction happened on Jan 07 ’25, when Company’s CHIEF EXECUTIVE OFFICER sold 7,489 for $42.82, making the entire transaction worth $320,644. This insider now owns 119,359 shares in total.
Mirum Pharmaceuticals Inc (MIRM) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.79% per share during the next fiscal year.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Trading Performance Indicators
Here are Mirum Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.07, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Mirum Pharmaceuticals Inc (MIRM)
Looking closely at Mirum Pharmaceuticals Inc (NASDAQ: MIRM), its last 5-days average volume was 0.5 million, which is a jump from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 54.99%. Additionally, its Average True Range was 1.59.
During the past 100 days, Mirum Pharmaceuticals Inc’s (MIRM) raw stochastic average was set at 59.35%, which indicates a significant decrease from 97.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.54% in the past 14 days, which was lower than the 37.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.75, while its 200-day Moving Average is $36.10. However, in the short run, Mirum Pharmaceuticals Inc’s stock first resistance to watch stands at $45.17. Second resistance stands at $46.33. The third major resistance level sits at $48.57. If the price goes on to break the first support level at $41.77, it is likely to go to the next support level at $39.53. Should the price break the second support level, the third support level stands at $38.37.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Key Stats
With a market capitalization of 2.11 billion, the company has a total of 48,005K Shares Outstanding. Currently, annual sales are 186,370 K while annual income is -163,420 K. The company’s previous quarter sales were 90,380 K while its latest quarter income was -14,240 K.
